Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
173 results about "NERVOUS DISORDERS" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Parkinson’s disease is a nervous system disorder whose main symptoms include tremors, rigidity of the trunk and extremities, slow movement and balance disorders. This nervous system disorder arises from a loss of brain cells that produce dopamine.
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
Owner:AVANIR PHARMA
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
Compositions, kits, methods, and systems to induce, maintain, monitor, and interpret a continuous, un-fragmented REM sleep state in humans, generate dreams, recover sleep, create brain neuronal plasticity and activate the brain for cognition enhancement and mood stabilization are described. If potentially combined with other medications, a platform is provided to develop new research and therapies in many fields treating the human brain. The procedure reliably and quickly generates a Continuous REM Sleep cycle of pre-determined time or indefinite duration depending on therapeutic goals, allowing the patient to experience a qualitatively superior dream sleep in a shortened period of time compared to a natural sleep cycle. Profuse positive (pleasant) dreams are produced as well. REM sleep, dreams and sleep recovery can be reliably generated, and various sleep, psychological and neurological illnesses and disorders can be treated or prevented either solely by this method or in combination with additional agents.
Owner:CHOW HARRISON
Neurological functions
ActiveUS20060052428A1Easy to useGood curative effectOrganic active ingredientsBiocideEpileptic disorderNERVOUS DISORDERS
Owner:CHEZ MICHAEL
Methods and systems for treatment of neurological diseases of the central nervous system
InactiveUS20050208090A1Reduce degradationAdequate transportNervous disorderPeptide/protein ingredientsSystems designActive enzyme
The present invention is directed to methods and systems for the treatment of inborn genetic errors or other defects that cause deficiencies of active enzymes or proteins within the cells of the central nervous system. Such methods and systems generally comprise an implantable catheter system designed for the chronic delivery of specially formulated proteins to intrathecal, intracerebroventricular, and / or intraparenchymal regions of the central nervous system. The invention has application in the neuropathic aspects of the broad category of lysosomal storage diseases. These genetic based diseases are the result of insufficient enzyme activity to catabolize specific substances, which thereby accumulate in the cellular lysosomes.
Owner:MEDTRONIC INC
Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
InactiveUS20050255113A1Inhibition formationReduce formationOrganic active ingredientsNervous disorderDiseaseNeurological disorder
The invention provides methods for inhibiting the formation of undesired intracellular polypeptide complexes or aggregates associated with neurological disorders using an intrabody.
Owner:HEALTH RES INC
Methods and apparatus for relieving headaches, rhinitis and other common ailments
InactiveUS20050279350A1Relieve symptomsQuick reliefOrganic active ingredientsSenses disorderHigh concentrationDisease
Apparatus, methods, and kits for treating symptoms associated with common ailments, such as headaches, rhinitis, asthma, epilepsy, nervous disorders and the like, are provided. The apparatus comprises dispensers for carbon dioxide and other therapeutic gases. The methods comprise delivering small volumes of these gases to patients in a manner where the gas infuses into a body region in order to bathe the mucous membranes therein. It has been found that even very short exposure of patients to small volumes and high concentrations of such gases can provide significant relief from symptoms.
Owner:CAPNIA INC
Pattern analysis of retinal maps for the diagnosis of optic nerve diseases by optical coherence tomography
Methods for analyzing retinal tomography maps to detect patterns of optic nerve diseases such as glaucoma, optic neuritis, anterior ischemic optic neuropathy are disclosed in this invention. The areas of mapping include the macula centered on the fovea, and the region centered on the optic nerve head. The retinal layers that are analyzed include the nerve fiber, ganglion cell, inner plexiform and inner nuclear layers and their combinations. The overall retinal thickness can also be analyzed. Pattern analysis are applied to the maps to create single parameter for diagnosis and progression analysis of glaucoma and optic neuropathy.
Owner:USC STEVENS UNIV OF SOUTHERN CALIFORNIA
Noveltreatment for neurological disorders
InactiveUS20100172919A1Lower protein levelLower Level RequirementsAntibacterial agentsBiocideAmyloid betaBiomarker (petroleum)
Provided are novel drugs and methods in the treatment as well as diagnosis of neurological disorders such as Alzheimer's disease and amyloid-beta pathology / amyloidosis. More specifically, the use of erythropoietin and analogs thereof for the treatment of Aβ peptide related brain impairments is described. Furthermore, the use of claudin-5 and variants thereof as biomarker for Alzheimer's disease and for the progression of Alzheimer's disease, respectively, is provided.
Owner:UNIV ZURICH
Animal model simulating neurologic disease
InactiveUS20050102708A1Compounds screening/testingPeptide/protein ingredientsPharmacometricsButhionine sulfoximine
The present invention relates to the development of a pharmacological non-human animal model that associates memory loss to histopathological features found in the brain of a subject having Alzheimer's Disease. In one embodiment, a four-week continuous infusion of a Fe2+, Aβ42 and buthionine sulfoximine (FAB) solution in the left ventricle of young adult Long-Evans rats induced memory impairment accompanied by increased hyperphosphorylated Tau protein levels in cerebrospinal fluid. Brains from treated animals displayed neuritic plaques, tangles, neuronal loss, astrogliosis and microgliosis in hippocampus and cortex. The present invention may be utilized in evaluating preventive, therapeutic and diagnostic means for neurologic diseases.
Owner:SAMARITAN PHARMA +1
Patient management device, system and method
InactiveUS8821416B2Facilitate communicationSimplified user interfaceDrug and medicationsPerson identificationDiseasePatient input
Owner:CUNCTUS +1
Compositions and Methods for Identifying Autism Spectrum Disorders
InactiveUS20130012403A1Nucleotide librariesMicrobiological testing/measurementMicrorna profilingMicroRNA Profile
The compositions and methods described are directed to microRNA chips having a plurality of different oligonucleotides with specificity for genes associated with autism spectrum disorders. The invention further provides methods of identifying microRNA profiles for neurological and psychiatric conditions including autism spectrum disorders, methods of treating such conditions, and methods of identifying therapeutics for the treatment of such neurological and psychiatric conditions.
Owner:GEORGE WASHINGTON UNIVERSITY
Differential diagnosis of neurological diseases
InactiveUS6670137B2Nervous disorderPeptide/protein ingredientsDementia with Lewy bodiesNervous system
Owner:INNOGENETICS NV
Xenotransplant for CNS therapy
InactiveUS20050265977A1Risk minimizationIncrease productionBiocideNervous system cellsNervous systemMammal
Disclosed are implant compositions and methods for treatment of neurological diseases of the central nervous system of a mammal.
Owner:NEUROTROPHINCELL
Systems and methods for monitoring a patient's neurological disease state
InactiveUS9375573B2Reducing time and number of interactionSatisfactory treatmentHead electrodesImplantable neurostimulatorsMedicineDisease status
The present invention provides a system for providing neurological disease state information to a patient. The system comprises one or more sensors that sense at least one signal that comprise feature(s) that are indicative of a neurological disease state. A signal processing assembly is in communication with the one or more sensors and processes the at least one signal to estimate the neurological disease state. A patient interface module is in communication with the signal processing assembly and communicates with a patient an output that is indicative of the patient's estimated neurological disease state.
Owner:CYBERONICS INC
Slow intraventricular delivery
InactiveUS20090123451A1Lower Level RequirementsOrganic active ingredientsNervous disorderAnesthetic AgentDiagnostic agent
Neurological diseases, including lysosomal storage diseases, can be successfully treated using intraventricular delivery of the therapeutic agents to bypass the blood-brain barrier. Similarly, diagnostic agents and anesthetic agents can be delivered to the brain in this manner. The administration can be performed slowly to achieve maximum effect. Such administration permits greater penetration of distal portions of the brain.
Owner:GENZYME CORP
2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders
This invention relates to new 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives of formula (1) having anticonvulsant activity which are useful as therapeutic agents for the treatment or prevention of epilepsy and other neurological disorders. The invention also concerns processes for preparing these derivatives and novel intermediates used in the preparation of these derivatives.
Owner:UCB SA
Neuromuscular stimulation system
A wearable neuromuscular stimulation and neuroprosthetic system and device for treating spinal cord injury, stroke, and other neurological conditions; and for the management of chronic pain. This invention provides a system for transcutaneous neuromuscular stimulation and typically comprises a wearable item that further includes a flexible, non-conductive material; at least one flexible, generally flat electrode attachable to or embedded within the wearable item; and a programmable electrical stimulation device connectable to the electrode(s). Each electrode typically includes a silver-impregnated or silver-treated material.
Owner:MUCCIO PHILIP E
Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and / or to stabilize β-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and / or compositions in the treatment of subjects having a neurological disease and / or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and / or Chir99021 in the treatment of subjects having a neurological disease and / or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.
Owner:MASSACHUSETTS INST OF TECH +1
Novel cyclosporin derivatives and uses thereof
The present invention relates to a compound of the Formula (I)):or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.
Owner:S&T GLOBAL
Reverse-turn mimetics and composition and methods relating thereto
Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins having the following structure are disclosed: wherein A, R1, R2, R2a and R3 are as defined herein. Such compounds have utility over a wide range of fields, including use as diagnostic and therapeutic agents. In particular, compounds of this invention are useful in pharmaceutical compositions as anti-inflammatory agents as well as inhibitors of central nervous disorders. Libraries containing the compounds of this invention are also disclosed, as well as methods for screening the same to identify biologically active members.
Owner:PRISM BIOLAB
Aralkyl piperidine (piperazidine) derivate and use thereof in mental disease treatment
InactiveCN101302214AHigh affinityHigh antagonistic activityOrganic active ingredientsNervous disorderDiseaseSchizophrenia
The invention discloses an aralkyl piperidine (oxazine) derivative and an application of the derivative in treating neurological and mental diseases. Pharmacological tests show that the derivative has a good effect of resisting schizophrenia and little toxicity. The derivative is free alkali or salt of a compound having the following structure general formula.
Owner:JIANGSU HENGYI PHARMA +1
Supplements for pain management
ActiveUS7871609B2Reduces pain and inflammationReduce inflammationPeptide/protein ingredientsAntipyreticDietary supplementArthritis
Dietary supplements, compositions and methods of administering the supplements to reduce pain, inflammation and stiffness in said mammal within a few hours. The supplements and compositions can include a combination of an amino acid, vitamins, herbs and enzymes. The composition / supplement can be put in capsule form and when administered to mammals can reduce these symptoms within approximately two hours. reducing the pain and inflammation associated with chronic joint discomfort, chronic low back pain, muscle strain, arthritis, sports injuries, normal everyday bumps and bruises. The novel composition has also been shown to be very effective in reducing monthly menstrual symptoms (PMS). The novel composition can also have benefits for other ailments such as but not limited to Osteoarthritis, Cardiovascular disease, Neurological ailments, Alzheimer disease, and Cancer.
Owner:RELEANA LLC
Point-of-care tele monitoring device for neurological disorders and neurovascular diseases and system and method thereof
Disclosed herein an improved systems and methods using point-of-care (POC), IoT (Internet of Things) enabled device(s) which captures different bio-signals simultaneously as distinct signals, by targeting same neurovascular substrate. The synchronized streaming of the data for live analysis or recording in the tele neuro-monitoring platform are jointly processed in an Artificial Intelligence (AI) based big-data platform under a closed loop, bi-directional, decision tree based system for brain / neurological function status monitoring (continuously and / or intermittently) leading to online POC diagnosis, severity classification, and prognosis of neurological disorders and neurovascular diseases.
Owner:SENGUPTA RAJIB +2
Combination product for the treatment of neurological and/or psychiatric disorders
ActiveUS20200397752A1Promoting neurogenesisOrganic active ingredientsNervous disorderDiseaseNeurogenesis
The present application provides a combination product for the treatment and / or prevention of psychiatric and / or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and / or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and / or removes the hallucinogenic and / or psychedelic side effects caused by the first compound.
Owner:TERRAN BIOSCIENCES INC
Neural specific s100b for biomarker assays and devices for detection of a neurological condition
InactiveUS20150141528A1Auxiliary diagnosisBiocideBioreactor/fermenter combinationsDisplay deviceNeuronal disease
An in vitro diagnostic (IVD) device is used to detect the presence of and / or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and / or neuronal disorders in a biological sample, such as whole blood, plasma, serum, and / or cerebrospinal fluid (CSF). An IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format, either to a display device or to a storage device internal or external to the IVD.
Owner:BANYAN BIOMARKERS INC
Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases
The invention relates to medicinally used substances which specifically inhibit peptidases splitting ala-p-nitroanilide. The invention further relates to the use of at least one such substance or at least one pharmaceutical or cosmetic composition containing such a substance for preventing and treating diseases, especially diseases with an overshooting immune response (autoimmune diseases, allergies, and transplant rejections), other chronic inflammatory diseases, neuronal diseases, brain damages, skin diseases (acne and psoriasis, among others), tumor diseases, and special viral infections (including SARS).
Owner:INSTITUT FUR MEDIZINTECH MAGDEBURG IMTM +1
Agilawood compound essential oil capable of improving sleeping
InactiveCN102210789APromote circulationRelax muscle tensionNervous disorderPlant ingredientsInsomniaRhythm
The invention belongs to the technical field of health products, and in particular relates to agilawood compound essential oil capable of improving sleeping, prepared by uniformly mixing agilawood essential oil, lavender essential oil, camomile essential oil and grape seed oil. Because natural plant extracts are scientifically matched, the agilawood compound essential oil can effectively improve the sleeping quality and prolong the sleeping time, and is mainly used for nervous disorder insomnia caused by factors such as increased working pressure, accelerated life rhythm, high frequency of night life and the like.
Owner:INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI HAINAN BRANCH +1
Method of Treating Neurological Conditions with Oleandrin
ActiveUS20180000852A1Prevent and reduce incidenceDisease diagnosisBiological testingOleandrinDisease
A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside, and optionally triterpene(s), to a subject. The cardiac glycoside can be present in a dosage form.
Owner:PHOENIX BIOTECH INC
Therapeutic agent for psychoneurotic disease
The present invention relates to a preventive and / or therapeutic agent for psychoneurotic diseases, comprising an EP3 antagonist represented by the general formula (I):(wherein the meanings of characters are defined in the description). This compound has an antagonistic potency against EP3 and exhibits efficacy through unusual action mechanism as a preventive and / or therapeutic agent for psychoneurotic disorder, psychosomatic disorder, anxiety disorder, depression and disorder caused by stress.
Owner:ONO PHARMA CO LTD
Patient Management Device, System And Method
InactiveUS20150190084A1Facilitate communicationSimplified user interfaceDrug and medicationsPerson identificationComputer hardwarePatient input
A portable apparatus for managing a plurality of events related to a patient and for recording and storing input data related to said events is disclosed. The portable apparatus comprises a man machine user interface; a timer unit; a control unit, arranged to provide an invitation to the patient as an instruction via the interface to perform a motion exercise, upon a trigger from the timer unit or upon a patient self initiation. In an embodiment the apparatus comprises a sensor to record measurements related to said motion exercise. Further, a storage unit is arranged to retrievably store patient input data and said measurements. This enables diagnosing a degree of a neurological disease or an effect of a medication on said neurological disease.
Owner:KIPAX
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com